rabies

PD 198306 is a selective inhibitor of MAPK/ERK-kinase (MEK) with antihyperalgesic effects. PD 198306 reduces the Streptozocin-induced increase in the level of active ERK1.

GRP-60367 is the first small molecule rabies virus (RABV) entry inhibitor, which has nanomolar effect on some RABV strains.

Rabies Virus Matrix Protein Fragment (RV-MAT), a polypeptide, selectively binds to the acetylcholine receptor (AChR) on the cell surface [1].

Rabies Virus Glycoprotein (TFA), a 29-amino acid-derived cell-penetrating peptide from the Rabies Virus Glycoprotein, can cross the blood-brain barrier (BBB) and enter brain cells.

Rabies Virus Glycoprotein is a 29 amino acid fragment generated from rabies virus glycoprotein (RVG). This peptide specifically binds to the acetylcholine receptor expressed by neuronal cells.

Rabies Virus Glycoprotein acetate is a useful organic compound for research related to life sciences and the catalog number is TP1871L.

RVG29, a peptide originating from Rabies Virus Glycoprotein, specifically targets the α-7 subunit of nicotinic acetylcholine receptors (AchR) on neuronal cells, thereby facilitating the transport of Mycobacterium tuberculosis antigens to antigen-presenting cells [1].

RVG-9R HCl is a 29-amino acid chimeric peptide, a derivative of rabies virus glycoprotein (RVG) with a positively charged nonyl-arginine motif added to its C-terminus, enabling siRNA delivery to neuronal cells.

Pseudorabies virus-IN-1 is a potent inhibitor of pseudorabies virus (PRV) with an EC50 of 0.29 nM, acting by targeting PRV deoxyribonucleic acid polymerase (DNA pol) to suppress PRV replication. It effectively inhibits PRV replication even at low concentrations (MIC80: 1.6-8 nM) and is useful for research on PRV infections.

GRP-60367 hydrochloride is a novel small-molecule entry inhibitor of rabies virus (RABV), exhibiting nanomolar potency against select RABV strains. This first-in-class compound effectively targets the RABV G protein [1].

Antiviral agent 15 (Compound 15f) is a Clofazimine derivative with antiviral activity, inhibiting the rabies virus (EC50: 1.45 μM) and pseudotyped SARS-CoV-2 (EC50: 14.6 μM).

Mazorelvimab (SYN023), a cocktail composed of the humanized monoclonal antibodies CTB011 and CTB012, targets the rabies virus (RABV) by binding to non-overlapping epitopes on the RABV's glycoprotein (G). This interaction showcases Mazorelvimab's potential in rabies prevention [1] [2].

Rafivirumab (CR57) is a monoclonal antibody targeting the rabies virus G protein, used in the study of rabies virus infection.

Docaravimab, an antibody designed to target the G-III epitope within the ectodomain of the Evelyn-Rockitniki-Abelseth (ERA) glycoprotein, is utilized in rabies research [1].

Foravirumab (CR4098) is a monoclonal antibody targeting rabies virus glycoprotein (RABV-G) for the study of infectious diseases such as rabies.

Zamerovimab (CTB011; SYN023), a composite of human monoclonal antibodies CTB011 and CTB012, targets distinct, non-overlapping epitopes on the rabies virus (RABV) glycoprotein, with CTB011 specifically binding to antigenic site III. This compound is applicable in rabies research [1].

Ormutivimab (rhRIG), a recombinant human monoclonal antibody designed to target the rabies virus, effectively neutralizes various strains and demonstrates strong efficacy as a post-exposure prophylaxis (PEP) treatment in model studies [1] [2].

Miromavimab (M777-16-3) is a monoclonal antibody (mAb) that targets the G-II epitope within the ectodomain of the rabies virus strain ERAGP [1].

DSPE-PEG5000-RVG29 is a PEG compound comprised of DSPE and rabies virus glycoprotein 29 (RVG29). RVG29 specifically binds to nicotinic acetylcholine receptors (nAChR) at the blood-brain barrier (BBB) and facilitates passage through the BBB.

DSPE-PEG2000-RVG29 is a PEG compound composed of DSPE and rabies virus glycoprotein 29 (RVG29). RVG29 specifically binds to nicotinic acetylcholine receptors (nAChR) at the blood-brain barrier (BBB) and can traverse the BBB.

DSPE-PEG1000-RVG29 is a PEG compound composed of DSPE and rabies virus glycoprotein 29 (RVG29). RVG29 can specifically bind to nicotinic acetylcholine receptors (nAChR) at the blood-brain barrier (BBB) and cross the BBB.

DSPE-PEG3400-RVG29 is a PEG compound composed of DSPE and rabies virus glycoprotein 29 (RVG29). RVG29 specifically binds to nicotinic acetylcholine receptors (nAChR) at the blood-brain barrier (BBB) and enables passage through the BBB.

Peptide VF13N is a synthetic rabies virus glycoprotein T helper cell epitope.

RVG29-Cys is a peptide derived from rabies virus glycoprotein (RVG) that specifically binds to nicotinic acetylcholine receptors (nAchR) on neural cells. It is employed to functionalize lipid nanoparticles (LNPs) via thiol-maleimide click chemistry for targeting nAchR present on the blood-brain barrier (BBB). mRNA LNPs functionalized with RVG29-Cys demonstrate enhanced transfection efficiency in cultured brain endothelial and neuronal cells, as well as in mice following systemic administration.